The main hormonal alterations found in PCOS include increased luteinizing hormone/follicle stimulating hormone (LH/FSH) ratio, hyperandrogenism, and insulin resistance, with consequent compensatory hyperinsulinemia, occasionally independent of body weight [2, 8]
Reductions of this magnitude are rare in addiction medicine and whats remarkable is that the finding came from drugs initially designed for diabetes, later repurposed for obesity and never intended to treat addiction
Pharmacological interventions such as orlistat or GLP-1 receptor agonists may be considered for patients with BMI 30 kg/m who have not achieved adequate weight loss through lifestyle measures alone
For CJC-1295 with DAC, research protocols commonly reference doses in the range of 1-2mg per week, sometimes split into two administrations
The Medicare GLP-1 Bridge Program lets eligible Medicare Part D beneficiaries get Wegovy, Zepbound, or Foundayo for a $50 per month medication copay from July 1, 2026 through December 31, 2027
Tirzepatide has shown significant promise in clinical trials , not just for its primary function but also for weight loss